Which has better valuation and earnings, BHVN or ARVN?

Arvinas has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Arvinas $262.60M 2.30 -$80.80M $0.10 93.60

Is BHVN or ARVN more profitable?

Arvinas has a net margin of 2.94% compared to Biohaven's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Arvinas 2.94% 1.91% 1.29%

Does the media favor BHVN or ARVN?

In the previous week, Biohaven had 10 more articles in the media than Arvinas. MarketBeat recorded 13 mentions for Biohaven and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Biohaven's score of -0.15 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ABCL or ARVN?

Arvinas has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbCellera Biologics $75.13M 46.20 -$146.41M -$0.54 N/A Arvinas $262.60M 2.30 -$80.80M $0.10 93.60

Does the media favor ABCL or ARVN?

In the previous week, AbCellera Biologics had 2 more articles in the media than Arvinas. MarketBeat recorded 5 mentions for AbCellera Biologics and 3 mentions for Arvinas. AbCellera Biologics' average media sentiment score of 1.03 beat Arvinas' score of 0.94 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARVN or STOK more profitable?

Arvinas has a net margin of 2.94% compared to Stoke Therapeutics' net margin of -753.60%. Arvinas' return on equity of 1.91% beat Stoke Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas 2.94% 1.91% 1.29% Stoke Therapeutics -753.60% -59.36% -51.46%

Does the media refer more to ARVN or STOK?

In the previous week, Stoke Therapeutics had 11 more articles in the media than Arvinas. MarketBeat recorded 14 mentions for Stoke Therapeutics and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Stoke Therapeutics' score of 0.28 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or ARVN?

In the previous week, Aurinia Pharmaceuticals had 9 more articles in the media than Arvinas. MarketBeat recorded 12 mentions for Aurinia Pharmaceuticals and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Aurinia Pharmaceuticals' score of 0.60 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ARVN or MESO?

Arvinas presently has a consensus price target of $14.17, suggesting a potential upside of 51.35%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.45 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ARVN or MESO?

Arvinas has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 2.30 -$80.80M $0.10 93.60 Mesoblast $17.20M 128.37 -$102.14M -$0.28 N/A

Is ARVN or MESO more profitable?

Arvinas has a net margin of 2.94% compared to Mesoblast's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Arvinas 2.94% 1.91% 1.29% Mesoblast N/A N/A N/A

Does the media refer more to ARVN or MESO?

In the previous week, Mesoblast had 5 more articles in the media than Arvinas. MarketBeat recorded 8 mentions for Mesoblast and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Mesoblast's score of 0.01 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Arvinas (ARVN) Competitors

$9.36 +0.34 (+3.77%)

As of 08/21/2026 04:00 PM Eastern

Compare

ARVN vs. BHVN, ABCL, STOK, AUPH, and MESO

Should you buy Arvinas stock or one of its competitors? Arvinas's main competitors and comparable companies include Biohaven (BHVN), AbCellera Biologics (ABCL), Stoke Therapeutics (STOK), Aurinia Pharmaceuticals (AUPH), and Mesoblast (MESO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arvinas compare to Biohaven?

Biohaven (NYSE:BHVN) and Arvinas (NASDAQ:ARVN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, Biohaven had 10 more articles in the media than Arvinas. MarketBeat recorded 13 mentions for Biohaven and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Biohaven's score of -0.15 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas has a net margin of 2.94% compared to Biohaven's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Arvinas	2.94%	1.91%	1.29%

Biohaven currently has a consensus target price of $21.75, suggesting a potential upside of 56.36%. Arvinas has a consensus target price of $14.17, suggesting a potential upside of 51.35%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

88.8% of Biohaven shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arvinas has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Arvinas	$262.60M	2.30	-$80.80M	$0.10	93.60

Summary

Arvinas beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Arvinas compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Arvinas (NASDAQ:ARVN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 7.3% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arvinas has a net margin of 2.94% compared to AbCellera Biologics' net margin of -248.83%. Arvinas' return on equity of 1.91% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Arvinas	2.94%	1.91%	1.29%

Arvinas has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	46.20	-$146.41M	-$0.54	N/A
Arvinas	$262.60M	2.30	-$80.80M	$0.10	93.60

In the previous week, AbCellera Biologics had 2 more articles in the media than Arvinas. MarketBeat recorded 5 mentions for AbCellera Biologics and 3 mentions for Arvinas. AbCellera Biologics' average media sentiment score of 1.03 beat Arvinas' score of 0.94 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

AbCellera Biologics currently has a consensus price target of $12.83, indicating a potential upside of 13.37%. Arvinas has a consensus price target of $14.17, indicating a potential upside of 51.35%. Given Arvinas' higher possible upside, analysts clearly believe Arvinas is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Summary

Arvinas beats AbCellera Biologics on 11 of the 16 factors compared between the two stocks.

How does Arvinas compare to Stoke Therapeutics?

Arvinas (NASDAQ:ARVN) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Arvinas presently has a consensus price target of $14.17, suggesting a potential upside of 51.35%. Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 37.04%. Given Arvinas' higher possible upside, equities analysts plainly believe Arvinas is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Stoke Therapeutics had 11 more articles in the media than Arvinas. MarketBeat recorded 14 mentions for Stoke Therapeutics and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Stoke Therapeutics' score of 0.28 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arvinas has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Arvinas has a net margin of 2.94% compared to Stoke Therapeutics' net margin of -753.60%. Arvinas' return on equity of 1.91% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

95.2% of Arvinas shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Stoke Therapeutics has lower revenue, but higher earnings than Arvinas. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.30	-$80.80M	$0.10	93.60
Stoke Therapeutics	$184.42M	11.30	-$6.89M	-$3.34	N/A

Summary

Arvinas beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Arvinas compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Arvinas (NASDAQ:ARVN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Arvinas' net margin of 2.94%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Arvinas	2.94%	1.91%	1.29%

Aurinia Pharmaceuticals has higher revenue and earnings than Arvinas. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$311.51M	7.11	$287.20M	$2.29	7.27
Arvinas	$262.60M	2.30	-$80.80M	$0.10	93.60

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals currently has a consensus price target of $17.67, indicating a potential upside of 6.11%. Arvinas has a consensus price target of $14.17, indicating a potential upside of 51.35%. Given Arvinas' higher possible upside, analysts clearly believe Arvinas is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Aurinia Pharmaceuticals had 9 more articles in the media than Arvinas. MarketBeat recorded 12 mentions for Aurinia Pharmaceuticals and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Aurinia Pharmaceuticals' score of 0.60 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Arvinas on 10 of the 16 factors compared between the two stocks.

How does Arvinas compare to Mesoblast?

Arvinas (NASDAQ:ARVN) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Arvinas has a net margin of 2.94% compared to Mesoblast's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Mesoblast	N/A	N/A	N/A

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arvinas presently has a consensus price target of $14.17, suggesting a potential upside of 51.35%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mesoblast had 5 more articles in the media than Arvinas. MarketBeat recorded 8 mentions for Mesoblast and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat Mesoblast's score of 0.01 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arvinas has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

Arvinas has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.30	-$80.80M	$0.10	93.60
Mesoblast	$17.20M	128.37	-$102.14M	-$0.28	N/A

Summary

Arvinas beats Mesoblast on 13 of the 17 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARVN vs. The Competition

Export

Metric	Arvinas	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$604.24M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	93.61	11.62	272.60	24.24
Price / Sales	2.30	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	1.07	16.80	13.05	6.20
Net Income	-$80.80M	-$12.50M	$3.47B	$348.59M
7 Day Performance	4.35%	3.29%	2.09%	0.08%
1 Month Performance	15.27%	8.23%	6.64%	3.88%
1 Year Performance	27.87%	55.05%	25.02%	16.98%

Arvinas Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARVN Arvinas	3.1012 of 5 stars	$9.36 +3.8%	$14.17 +51.4%	+27.9%	$604.24M	$262.60M	93.61	420
BHVN Biohaven	3.2482 of 5 stars	$14.58 -0.5%	$21.63 +48.3%	-10.9%	$2.21B	N/A	N/A	239	News Coverage Analyst Revision
ABCL AbCellera Biologics	2.307 of 5 stars	$9.34 +34.8%	$9.40 +0.6%	+157.9%	$2.12B	$75.13M	N/A	500	Positive News High Trading Volume
STOK Stoke Therapeutics	2.4461 of 5 stars	$32.23 -1.5%	$43.00 +33.4%	+65.1%	$2.11B	$184.42M	N/A	100	Analyst Forecast Insider Trade
AUPH Aurinia Pharmaceuticals	3.5142 of 5 stars	$15.45 -2.5%	$17.67 +14.3%	+35.7%	$2.11B	$283.05M	6.75	300	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARVN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arvinas (ARVN) Competitors

ARVN vs. BHVN, ABCL, STOK, AUPH, and MESO

How does Arvinas compare to Biohaven?

Summary

How does Arvinas compare to AbCellera Biologics?

Summary

How does Arvinas compare to Stoke Therapeutics?

Summary

How does Arvinas compare to Aurinia Pharmaceuticals?

Summary

How does Arvinas compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arvinas (ARVN) Competitors

ARVN vs. BHVN, ABCL, STOK, AUPH, and MESO

How does Arvinas compare to Biohaven?

Does the media favor BHVN or ARVN?

Is BHVN or ARVN more profitable?

Do analysts rate BHVN or ARVN?

Which has more risk & volatility, BHVN or ARVN?

Do institutionals & insiders hold more shares of BHVN or ARVN?

Which has better valuation and earnings, BHVN or ARVN?

Summary

How does Arvinas compare to AbCellera Biologics?

Do insiders and institutionals have more ownership in ABCL or ARVN?

Is ABCL or ARVN more profitable?

Which has preferable valuation and earnings, ABCL or ARVN?

Does the media favor ABCL or ARVN?

Which has more risk and volatility, ABCL or ARVN?

Do analysts rate ABCL or ARVN?

Summary

How does Arvinas compare to Stoke Therapeutics?

Do analysts recommend ARVN or STOK?

Does the media refer more to ARVN or STOK?

Which has more risk and volatility, ARVN or STOK?

Is ARVN or STOK more profitable?

Do institutionals & insiders have more ownership in ARVN or STOK?

Which has higher earnings and valuation, ARVN or STOK?

Summary

How does Arvinas compare to Aurinia Pharmaceuticals?

Is AUPH or ARVN more profitable?

Which has stronger earnings & valuation, AUPH or ARVN?

Do institutionals and insiders believe in AUPH or ARVN?

Do analysts rate AUPH or ARVN?

Does the media favor AUPH or ARVN?

Which has more risk and volatility, AUPH or ARVN?

Summary

How does Arvinas compare to Mesoblast?

Is ARVN or MESO more profitable?

Do insiders and institutionals hold more shares of ARVN or MESO?

Do analysts recommend ARVN or MESO?

Does the media refer more to ARVN or MESO?

Which has more risk and volatility, ARVN or MESO?

Which has higher earnings & valuation, ARVN or MESO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools